Asparaginase Toxicities in ALL
Symposium
Symposium

Asparaginase Toxicities in ALL

Rapid Identification, Management, and Patient/Family Partnerships to Improve Outcomes

Not a member of My prIME? Join now for instant access.

Meeting Overview

Get the latest updates on current and emerging asparaginase therapies in pediatric ALL at this interactive satellite symposium. A variety of topics will be discussed, including mechanism of action and pharmacokinetics, monitoring and management of asparaginase toxicities, and communication approaches specific to pediatric patients and their families. Attendees will have the opportunity to interact with expert faculty throughout the symposium.

This meeting will be held in conjunction with the Association of Pediatric Hematology/Oncology Nurses 42nd Annual Conference & Exhibit. Event staff will be glad to assist you with any special needs (physical, dietary, etc).

Date and Location

Saturday, September 15, 2018
12.45 PM – 2.00 PM

Chatham Ballroom ABC
Savannah International Trade & Convention Center
1 International Drive
Savannah, Georgia 31421

Date/Time

Date/Time

Saturday, September 15, 2018
12.45 PM – 2.00 PM

Location

Location

Savannah, Georgia, United States

CE

CE

1.2 Contact Hours

Saturday, September 15, 2018

12.45 PM Program overview
Belinda Mandrell, PhD, RN
12.50 PM Hematology Guru: What do you know about asparaginase toxicities?
Belinda Mandrell, PhD, RN
12.55 PM Asparaginase review
Katie Gettinger, MSN, RN, CPNP-PC
1.12 PM Interactive audience Q&A
1.17 PM Identification and management of asparaginase toxicities
Anna Lefebvre, MSN, RN, CPNP, CPON
Joan Ronan, MSN, RN, CPNP, CPON
1.40 PM Interactive audience Q&A
1.45 PM Assessing what you have learned from this activity: Have you increased your “guru” status?
Belinda Mandrell, PhD, RN
1.55 PM prIME Points™
Belinda Mandrell, PhD, RN
2.00 PM Adjourn

    Chair

  • Belinda Mandrell, PhD, RNSt Jude Children’s Research Hospital
    Memphis, Tennessee, United States
  • Faculty

  • Katie Gettinger, MSN, RN, CPNP-PCSt Louis Children’s Hospital
    St Louis, Missouri, United States
  • Anna Lefebvre, MSN, RN, CPNP, CPONDana Farber/ Boston Children’s Cancer and Blood Disorders Center
    Boston, Massachusetts, United States
  • Joan Ronan, MSN, RN, CPNP, CPONDana Farber/Boston Children’s Cancer and Blood Disorders Center
    Boston, Massachusetts, United States

There is no fee for this educational activity.

This educational activity is designed to meet the needs of registered nurses and advanced practice registered nurses who provide care for pediatric patients with acute lymphoblastic leukemia (ALL).

After successful completion of this educational activity, participants should be able to:

  • Discuss current and emerging asparaginase therapies for pediatric patients, including mechanism of action, structure, bacterial source, and pharmacokinetics
  • Implement clinical nursing approaches for the monitoring and management of asparaginase toxicities for pediatric patients with ALL
  • Describe best practices in patient/family education and communication to improve outcomes for pediatric patients with ALL

This educational activity is supported by a grant from Shire.

Continuing Education

Asparaginase Toxicities in ALL - prIME OncologyIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Provider

This activity is jointly provided by prIME Oncology and Postgraduate Institute for Medicine.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.